Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs DBV Technologies S.A. (DBVT)

Aclaris Therapeutics, Inc. and DBV Technologies S.A. are both Biotechnology companies. DBV Technologies S.A. is the larger, with a market value of $635.3M against $550.5M — 1.2× the size. DBV Technologies S.A. grew revenue faster over the last twelve months: −33.4% against −51.0%. Aclaris Therapeutics, Inc. has the higher net margin (−921.5% vs −5,547.3%) and the lower return on invested capital (−163.4% vs 0.00%). Across the 18 metrics below, Aclaris Therapeutics, Inc. leads on 15 and DBV Technologies S.A. on 3.

Valuation

Metric ACRS DBVT Biotechnology median
P/E n/m n/m 10.64
P/S 64.95 243.62 9.59
P/B 4.29 6.13 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 55.12 199.32 9.45
Earnings yield (15.51%) (30.62%) (34.69%)
Free cash flow yield (11.65%) (21.07%) (24.02%)

Profitability

Metric ACRS DBVT Biotechnology median
Gross margin 12.90% 100.00% 65.59%
Operating margin (1,050.16%) (5,571.63%) 0.00%
Net margin (921.50%) (5,547.30%) 0.00%
Free cash flow margin (756.50%) (5,131.50%) 0.00%
Return on equity (59.10%) (205.75%) (51.96%)
Return on assets (41.07%) (127.19%) (46.06%)
Return on invested capital (163.35%) 0.00% 0.00%

Growth

Metric ACRS DBVT Biotechnology median
Revenue growth (TTM) (51.04%) (33.42%) 4.59%
EPS growth (last fiscal year) 69.01% 10.26% 29.88%
Revenue growth, 5-year CAGR 3.84% (12.95%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS DBVT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 3.24 4.86
Net debt to EBITDA 1.20 1.35 1.01

Dividend

Metric ACRS DBVT Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ACRS DBVT Biotechnology median
Market cap 550.53m 635.31m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack